reports
Novonesis delivered a strong Q1 with 11% organic growth and confirms f...
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CEO, say...
Interim report Q1 2025
Interim report Q1 2025 Strong start to the year and confirmed full-year outlook Ester Baiget, President & CEO: “We delivered strong sales growth and earnings in the first quarter, with all four sales areas showing double-digit growth. Growth was driven by strong innovation especially in emerging markets, and with a continued broad pull for our solutions in developed markets. Synergies are materializing as expected and we are confirming the full-year outlook. We continue to see solid demand across the business, and our regional presence and resilient global setup enable us to respond with...
Resolutions from the Annual General Meeting 2025
Resolutions from the Annual General Meeting 2025 Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2024Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.Approval of the Remuneration Report for 2024 (advisory vote)Approval of the remuneration of members of the Board of Direc...
Invitation to the Annual General Meeting
Invitation to the Annual General Meeting The Annual General Meeting of Novonesis (Novozymes A/S) will be held on Thursday April 3, 2025 at 4:00 pm CEST at Gammel Venlighedsvej 14, DK-2970 Hoersholm, Denmark. There will also be access to the meeting from the entrance at Boege Alle 10-12, DK-2970 Hoersholm, Denmark. For further information, please read the attached PDF documents. Attachments
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please read the full announcement in PDF. Attachment
Election of employee representatives to the Board of Directors
Election of employee representatives to the Board of Directors The employees have conducted the election of employee representatives to the Board of Directors of Novonesis (Novozymes A/S). The following employee representatives (in alphabetical order after surname) were elected for the next four years: Robert Nøddeskov Jensen, Senior Operator - newly electedLars Bo Køppler, Technician - newly electedPreben Nielsen, Science Manager – re-electedFrederikke Rose Spenner, Production Engineer - newly elected As alternates to the employee representatives to the Board of Directors, the employe...
Trading by management and close relations of management
Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Please see attached the full announcement. Attachment
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.